Cart
sales@molnova.com
Erythromycin estolate
CAS No. 3521-62-8
Erythromycin estolate( —— )
Catalog No. M33353 CAS No. 3521-62-8
Erythromycin estolate
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 50MG | 31 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 111 | In Stock |
|
| 1G | 163 | In Stock |
|
Biological Information
-
Product NameErythromycin estolate
-
NoteResearch use only, not for human use.
-
Brief DescriptionErythromycin estolate
-
DescriptionErythromycin estolate, erythromycin derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3521-62-8
-
Formula Weight1056.39
-
Molecular FormulaC52H97NO18S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (94.66 mM; Ultrasonic )
-
SMILESCCCCCCCCCCCCOS(O)(=O)=O.CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2OC(=O)CC)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. David E. Kleiner, et al. Learn more about Erythromycin Estolate. Biomaterials and Medical Device - Associated Infections, 2015
molnova catalog
related products
-
DS86760016
DS86760016 is a novel selective bacterial leucyl-tRNA synthetase (LeuRS) inhibitor with IC50 of 0.38 uM (Escherichia coli, LeuRS).
-
AU-1235
AU-1235 is a novel, specific mycobacterial membrane protein large 3 (MmpL3) inhibitor.
-
F7H
F7H is a potent Frizzled receptor FZD7 antagonist with an IC50 value of 1.25 μM.F7H is a potent ligand for the transmembrane structural domain (TMD) of FZD7, with potential antitumor and bacteriostatic activity.
